Screener
Fulgent Genetics, Inc. FLGT Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Fulgent Genetics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 7:08 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-199065
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| (unaudited) | ||
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $23,399 | $50,193 |
| Marketable securities | 252,903 | 285,884 |
| Trade accounts receivable, net of allowance for credit losses of $21,420 as of March 31, 2026, and $21,411 as of December 31, 2025 | 69,277 | 84,762 |
| Prepaid income taxes | 109,165 | 107,099 |
| Other current assets | 24,298 | 22,552 |
Item 1. Financial Statements.
FAQ
- What is Fulgent Genetics, Inc.'s cash & equivalents?
- Fulgent Genetics, Inc. (FLGT) reported cash & equivalents of $23.4M in Q1 2026.
- How has Fulgent Genetics, Inc.'s cash & equivalents changed year-over-year?
- Fulgent Genetics, Inc.'s cash & equivalents decreased by 65.2% year-over-year, from $67.28M to $23.4M.
- What is the long-term trend for Fulgent Genetics, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Fulgent Genetics, Inc.'s cash & equivalents has grown at a -10.5% compound annual growth rate (CAGR), from $87.43M to $50.19M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Fulgent Genetics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude